GIS.F - Gilead Sciences, Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
56.80
-1.23 (-2.12%)
At close: 7:37PM CEST
Stock chart is not supported by your current browser
Previous Close58.03
Open58.15
Bid0.00 x 50000
Ask0.00 x 50000
Day's Range56.80 - 58.15
52 Week Range53.00 - 68.59
Volume50
Avg. Volume991
Market Cap71.006B
Beta (3Y Monthly)0.67
PE Ratio (TTM)12.31
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.26 (3.93%)
Ex-Dividend Date2019-09-12
1y Target EstN/A
  • Financial Times

    Gilead to challenge US patents on HIV drug Truvada

    Gilead Sciences, the maker of HIV drug Truvada, is moving to challenge patents held by the US government on the preventive use of the drug, which is known as PrEP, amid criticism it used publicly-funded research to bring the drug to market at too steep a price. In a statement on Wednesday, the drugmaker said it strongly believes that the patents granted to HHS for two prophylactic uses of the drug are not valid. Gilead’s petition to the US Patent and Trademark Office is to request a so-called inter partes review, which re-examines the claims in a patent to determine if they are valid.

  • Zacks Small Cap Research

    DRRX: Gilead Agreement, Near-Term Value-Inflection Opportunities Make DRRX Particularly Attractive at Current Valuation

    Durect Corp (DRRX) reported financial results for their second quarter ending June 30th and provided a pipeline development update. ‣ Gilead, HIV/HBV-SABER licensing agreement: on July 22nd DRRX announced an out-licensing agreement with Gilead Sciences, Inc (GILD) related to their SABER (controlled drug delivery) technology in the development of a long-acting injectable HIV product. The agreement, which will pay DRRX $25M upfront and potentially up to another $145M in development and sales related milestones (in addition to tiered royalties on sales) for the initial injectable HIV product, comes after ~two years’ worth of feasibility related work between the parties.

  • Financial Times

    Gilead did not seek US exclusivity on PrEP with Truvada

    Gilead Sciences did not apply for exclusivity when it sought US approval for Truvada, a drug that could end the HIV epidemic, to be used as a preventive treatment in 2012, according to a review of federal documents. Activists and legal experts say this lack of exclusivity and the publicly backed patents for the drug mean that Gilead’s effective monopoly in the US is invalid, and that generic alternatives could have been made available sooner. Analysis of the US Food and Drug Administration’s Orange Books, which among other information list drug patents as provided by pharmaceutical groups, shows no exclusivity for Truvada for preventive use, a treatment known as pre-exposure prophylaxis, or PrEP.

  • 3 Dividend Stocks That Should Pay You the Rest of Your Life
    Motley Fool

    3 Dividend Stocks That Should Pay You the Rest of Your Life

    Looking for payers you can count on? Then this trio should be right up your alley.

  • 3 Embarrassingly Cheap Dividend Stocks
    Motley Fool

    3 Embarrassingly Cheap Dividend Stocks

    High yields. Low valuations. But with a couple of downsides to be aware of.

  • MarketWatch

    Gilead's HIV drug Biktarvy approved in China

    Gilead Sciences Inc.'s drug Biktarvy has been approved for the treatment of HIV-1 in China, the company said Friday. The China National Medical Products Administration approved the drug as a treatment for patients with HIV-1 that isn't resistant to the integrase inhibitor class of drugs, emtricitabine or tenofovir. Biktarvy received marketing approval from the U.S. Food and Drug Administration and the European Commission in 2018. "Gilead is pleased that people living with HIV in China will now have our newest HIV treatment innovation as a treatment option," said Diana Brainard, Gilead's senior vice president of HIV and emerging viruses, in a statement. Gilead reported earnings last week that beat analysts' expectations. The company's HIV products continue to be a strong base for the company, with second-quarter HIV drug sales growing to $4 billion from $3.7 billion a year ago. Shares of Gilead have gained 3.6% in the year to date through Thursday, while the S&P 500 has gained 17.2%.

  • Gilead Stock Is Among The Biggest Biotech Stocks — But Should You Buy It?
    Investor's Business Daily

    Gilead Stock Is Among The Biggest Biotech Stocks — But Should You Buy It?

    Gilead is one of the biggest biotech companies. But recent news and earnings have been mixed. So, is Gilead stock a buy right now? Read on for a full analysis.

  • Medicare to cover expensive cancer cell therapies
    Reuters

    Medicare to cover expensive cancer cell therapies

    CMS, which runs Medicare - the federal government's health plan for Americans 65 and older - said it will cover the U.S. Food and Drug Administration-approved therapies when provided in healthcare facilities that have programs in place to track patient outcomes. The nationwide decision clears up "a lot of confusion" about coverage and will help patients get access to the novel therapies, known as CAR-T, CMS Administrator Seema Verma said during a conference call with reporters on Wednesday. Both Gilead's Yescarta and Novartis' Kymriah were approved in 2017 for certain kinds of lymphoma and leukemia.

  • Reuters

    UPDATE 1-Medicare to cover expensive cancer cell therapies

    The U.S. Centers for Medicare and Medicaid Services (CMS) on Wednesday said it has finalized a decision to cover expensive cancer cell therapies sold by Gilead Sciences Inc and Novartis AG. CMS, which runs Medicare - the federal government's health plan for Americans 65 and older - said it will cover the U.S. Food and Drug Administration-approved therapies when provided in healthcare facilities that have programs in place to track patient outcomes. The nationwide decision clears up "a lot of confusion" about coverage and will help patients get access to the novel therapies, known as CAR-T, CMS Administrator Seema Verma said during a conference call with reporters on Wednesday.

  • Reuters

    UPDATE 1-FDA panel backs Gilead's HIV prevention drug Descovy, except in women

    An FDA advisory panel on Wednesday voted in favor of Gilead Sciences Inc's combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men. The treatment, Descovy, is a combination of emtricitabine and tenofovir alafenamide, and is already approved to treat chronic HIV. When asked to assess the efficacy of Descovy for pre-exposure prophylaxis (PrEP) of HIV in men and transgender women who have sex with men, a patient population that forms the largest component of the PrEP market, the panel voted 16-2 in favor.

  • Reuters

    FDA panel backs Gilead's HIV prevention drug for certain population

    Independent experts on an FDA advisory panel on Wednesday voted in favor of Gilead Sciences Inc's combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men. The treatment, Descovy, is a combination of emtricitabine and tenofovir alafenamide, and is an approved treatment for chronic HIV. The panel voted 16-2 in favor when asked to assess the efficacy of Descovy for pre-exposure prophylaxis (PrEP) of HIV in men and transgender women who have sex with men, who form the largest component of the PrEP market.

  • Reuters

    FOCUS-Patient groups push back against Gilead's pricey HIV prevention treatment

    Gilead Sciences Inc hopes to soon introduce a pricey new pill to prevent HIV in people at risk of contracting the infection, but the drugmaker faces opposition from an unusual source: patient advocates. Such groups have traditionally lobbied for insurance coverage of newer HIV drugs regardless of expense. A generic version of the current prevention pill, Truvada, is due in the United States in September 2020, which should bring down costs and give many more people access to the therapy, they say.

  • Here's Why Galapagos NV Rose 34.5% in July
    Motley Fool

    Here's Why Galapagos NV Rose 34.5% in July

    The Belgian biopharma bagged $5.1 billion from its most important partner.

  • Are Amgen and Gilead Sciences Better Buys After Second-Quarter Earnings?
    Motley Fool

    Are Amgen and Gilead Sciences Better Buys After Second-Quarter Earnings?

    These blue-chip biotechs delivered mixed reports Tuesday.

  • Gilead Sciences Reports Improving Revenue in the 2nd Quarter
    Motley Fool

    Gilead Sciences Reports Improving Revenue in the 2nd Quarter

    The big biotech reported stronger revenue thanks primarily to its HIV drug, Biktarvy, and upped its full-year sales guidance.

  • Gilead earnings show surprising sales increase amid massive change
    MarketWatch

    Gilead earnings show surprising sales increase amid massive change

    Gilead Sciences Inc. reported a surprising gain in revenue Tuesday afternoon and beat earnings expectations, sending shares about 2% higher in after-hours trading.

  • Motley Fool

    After Hours: Apple, Mastercard, and Gilead Sciences Report Earnings

    The three giants in their respective industries posted generally better-than-expected results.

  • How A Key Franchise Helped Gilead's Quarterly Sales To Inch Up
    Investor's Business Daily

    How A Key Franchise Helped Gilead's Quarterly Sales To Inch Up

    Gilead earnings of $1.82 per share, minus some items, on $5.69 billion in sales topped forecasts Tuesday. The large biotech company also raised its full-year guidance for product sales.

  • Barrons.com

    Gilead Sciences Beats Second-Quarter Earnings Expectations

    The biotech company, which slightly raised its projected sales for the full fiscal year, attributed its earnings growth to sales of its HIV drugs.

  • Gilead results beat Street estimates as demand grows for HIV drug
    Reuters

    Gilead results beat Street estimates as demand grows for HIV drug

    California-based Gilead said it now expects 2019 sales of $21.6 billion to $22.1 billion in 2019, up from its prior forecast of $21.3 billion to $21.8 billion. The biotechnology company said second-quarter adjusted earnings were $1.82 per share, beating the average analyst estimate by 10 cents, according to IBES data from Refinitiv. "Gilead's results were very solid.

  • Reuters

    UPDATE 2-Gilead results beat Street estimates as demand grows for HIV drug

    Gilead Sciences Inc beat Wall Street estimates for second-quarter revenue and profit on Tuesday, driven by higher sales of HIV treatments, and the U.S. drugmaker raised its full-year sales forecast. California-based Gilead said it now expects 2019 sales of $21.6 billion to $22.1 billion in 2019, up from its prior forecast of $21.3 billion to $21.8 billion. The biotechnology company said second-quarter adjusted earnings were $1.82 per share, beating the average analyst estimate by 10 cents, according to IBES data from Refinitiv.

  • Gilead and Amgen will report second-quarter earnings after the closing bell. Here’s what to expect
    MarketWatch

    Gilead and Amgen will report second-quarter earnings after the closing bell. Here’s what to expect

    Drugmakers Gilead Sciences Inc. and Amgen Inc. are scheduled to report earnings Tuesday after the market close.

  • Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments
    Reuters

    Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments

    Unusually high numbers of U.S. lymphoma patients are choosing experimental treatments over expensive cell therapies sold by Gilead Sciences Inc and Novartis AG, new data shows, helping explain why sales of the two products have not met rosy expectations. Both Gilead's Yescarta and Novartis's Kymriah - which are part of a class of therapies known in the medical field as "CAR-T" - were approved in 2017.

  • Reuters

    FOCUS-Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments

    Unusually high numbers of U.S. lymphoma patients are choosing experimental treatments over expensive cell therapies sold by Gilead Sciences Inc and Novartis AG, new data shows, helping explain why sales of the two products have not met rosy expectations. Both Gilead's Yescarta and Novartis's Kymriah - which are part of a class of therapies known in the medical field as "CAR-T" - were approved in 2017.